THE LONG DAWN

Dispatches / Cancer

The long siege of cancer

ERAS‑0015 shrank tumours in early pancreatic and lung cancer testing

For forty years the RAS protein was called undruggable. A second molecule built to reach it is now being tested in people.

Phase 1Company-reported · not peer reviewed

What happened

  • Erasca, a San Diego drugmaker, reported early results for ERAS‑0015, a once-daily pill aimed at mutant RAS, the driver found in about 95% of pancreatic cancers.
  • As reported by CTV News: tumours shrank substantially in 44% of 25 people with advanced pancreatic cancer on a 32 mg daily dose, and in 3 of 5 people with lung cancer who had already had immunotherapy and chemotherapy.
  • Erasca says late-stage trials of ERAS‑0015 and a second drug, ERAS‑4001, start in 2027. Princess Margaret Cancer Centre in Toronto is expected to be a site.

What we don't know yet

  • These are company-reported numbers from a phase 1 trial. They have not been peer reviewed.
  • Tumour shrinkage is not the same as living longer. There is no control group yet.
  • Erasca's April 2026 update reported one death from treatment-related lung inflammation (pneumonitis), per a summary of the company's call.

Primary sources

Not medical advice. This is a summary of published results, not a recommendation. Ask your own doctor whether any treatment or trial fits you. To look for trials near you, search ClinicalTrials.gov or the WHO trial registry portal.